Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.
Investigators noted evident racial and ethnic disparities among patients with high prostate-specific antigen levels who received subsequent prostate MRI imaging.
Black veterans within the United States who could stand to highly benefit from definitive treatment were found to be less likely to undergo treatment than non-Black populations.
CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.
Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.
These data in Nature Communications found that Black men may derive survival benefits from immunotherapy treatment.
According to researchers, these immuno-oncologic differences may aid in developing a genomically adaptive approach to treating prostate cancer in this patient population.
“Our findings suggest that distinct genetic alterations in the prostate cancers of African American men, in comparison to white men, may contribute to more aggressive prostate cancer and could lead to a higher mortality rate,” said study senior author Jianfeng Xu, DrPH.
Black race was associated with improved prostate cancer-specific mortality and all-cause mortality among men with nonmetastatic prostate cancer who received radiation therapy in this large equal-access health care system.